You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,410,159


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,410,159
Title:Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof
Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
Inventor(s): Kirsch; Christoph (Cologne, DE), Logemann; Elke (Pulheim-Dansweiler, DE), Hahlbrock; Klaus (Freiburg, DE), Rushton; Paul (Brookings, SD), Somssich; Imre (Cologne, DE)
Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE)
Application Number:13/930,387
Patent Claims:1. A chimeric promoter capable of local gene expression in plants of an operably linked nucleic acid sequence, wherein the expression is induced by a pathogen elicitor treatment, a pathogen infection, or both, wherein the chimeric promoter comprises: (i) at least one cis-acting element sufficient to direct: pathogen-elicitor-specific expression of the nucleic acid sequence, pathogen-infection-specific expression of the nucleic acid sequence, or both, wherein the at least one cis-acting element comprises the nucleotide sequence of SEQ ID NO: 3 or 4, and (ii) a minimal promoter.

2. The chimeric promoter according to claim 1, further comprising at at least one additional cis-acting element, said additional cis-acting element consisting of the nucleotide sequence selected from the group consisting of the nucleotide sequences of one of SEQ ID NO: 1-16.

3. The chimeric promoter of claim 1, wherein the minimal promoter is selected from the group consisting of a CaMV35S promoter, a CHS promoter, a PR1 promoter, and a hcbt2 promoter.

4. The chimeric promoter according to claim 1, wherein the at least one cis-acting element comprises two copies of the nucleotide sequence of SEQ ID NO: 3 or 4.

5. The chimeric promoter of claim 2, wherein said chimeric promoter comprises homo- and/or hetero-multimeric forms of said at least one cis-acting element and said at least one additional cis-acting element.

6. The chimeric promoter of claim 1, wherein the distance between said at least one cis-acting element and said minimal promoter is 12 to 300 base pairs.

7. The chimeric promoter of claim 2, wherein at least two cis-acting elements are separated by a spacer, wherein the spacer is (a) from 4 to 10 or (b) about 50 to about 1000 base pairs, and wherein the at least two cis-acting elements are two of said at least one cis-acting element, two of said at least one additional cis-acting element, or one each of said at least one cis-acting element and said at least one additional cis-acting element.

8. The chimeric promoter of claim 5, wherein said homo- and/or hetero-multimeric form is a dimer or tetramer.

9. A recombinant gene comprising the chimeric promoter of claim 1.

10. The recombinant gene of claim 9, wherein at least one of the at least one cis-acting elements is located in the 5'- or 3'-untranslated region or in an intron of the recombinant gene.

11. The recombinant gene of claim 9, wherein the chimeric promoter is operatively linked to a heterologous DNA sequence, and wherein said heterologous DNA sequence encodes a (poly)peptide, a cytotoxic protein, an antibody, an antisense RNA, a sense RNA, a ribozyme, a transcription factor, a protease, a nuclease, a lipase, or a polymerase.

12. A vector comprising the chimeric promoter of claim 1.

13. A transgenic plant cell comprising the chimeric promoter of claim 1 or the vector of claim 12.

14. A transgenic plant or plant tissue comprising the transgenic plant cell of claim 13.

15. A harvestable part of a transgenic plant comprising the transgenic plant cell of claim 13.

16. A propagation material of a transgenic plant comprising the transgenic plant cell of claim 13.

17. The chimeric promoter of claim 1, wherein the distance between said at least one cis-acting element and said minimal promoter is 25 to 70 base pairs.

18. The chimeric promoter of claim 1, wherein the distance between said at least one cis-acting element and said minimal promoter is 40 to 60 base pairs.

19. A method for the production of a transgenic plant, a transgenic plant cell or a transgenic plant tissue comprising introducing the chimeric promoter of claim 1 into the genome of a plant, a plant cell or a plant tissue to produce the transgenic plant, the transgenic plant cell or the transgenic plant tissue.

20. A method for the production of a transgenic plant, a transgenic plant cell or a transgenic plant tissue comprising introducing the recombinant gene of claim 9 into the genome of a plant, a plant cell or a plant tissue to produce the transgenic plant, the transgenic plant cell or the transgenic plant tissue.

21. A method for the production of a transgenic plant, a transgenic plant cell or a transgenic plant tissue comprising introducing the vector of claim 12 into the genome of a plant, a plant cell or a plant tissue to produce the transgenic plant, the transgenic plant cell or the transgenic plant tissue.

22. An isolated cis-acting element sufficient to direct pathogen-elicitor-specific expression, pathogen-infection-specific expression, or both, consisting of the nucleotide sequence of SEQ ID NO: 3 or 4.

23. A chimeric promoter obtained by a method of rendering a promoter of a gene responsive to pathogens comprising inserting at least one cis-acting element sufficient to direct pathogen-elicitor-specific expression, pathogen-infection-specific expression, or both, into the promoter of said gene, wherein the at least one cis-acting element comprises the nucleotide sequence of SEQ ID NO: 3 or 4 to produce the chimeric promoter.

24. An isolated chimeric promoter to render a gene responsive to pathogens, obtained by a method comprising inserting at least one cis-acting element sufficient to direct pathogen-elicitor-induced expression, pathogen-infection induced expression, or both, of an operably linked nucleic acid, into the promoter of said gene, wherein the at least one cis-acting element comprises the nucleotide sequence of SEQ ID NO: 3 or 4.

25. A recombinant gene wherein the isolated chimeric promoter of claim 24 is linked to a coding sequence of a gene.

26. A vector wherein the isolated chimeric promoter of claim 24 is linked to vector sequences.

27. A method for the production of a transgenic plant, a transgenic plant cell or a transgenic plant tissue, wherein the method comprises: introducing the isolated chimeric promoter of claim 24 into the genome of a plant, a plant cell or a plant tissue to produce the transgenic plant, the transgenic plant cell or the transgenic plant tissue.

28. A chimeric promoter obtained by a method of rendering a promoter of a gene responsive to pathogens comprising inserting at least one cis-acting element sufficient to direct pathogen-elicitor-specific expression, pathogen-infection-specific expression, or both, into the promoter of said gene, wherein the at least one cis-acting element comprises two copies of the nucleotide sequence of SEQ ID NO: 3 or 4, or a combination of one copy of the nucleotide sequence of SEQ ID NO: 3 or 4 and one copy selected from the group consisting of the nucleotide sequence of SEQ ID NO: 1-16 to produce the chimeric promoter.

29. A method of rendering a promoter of a gene responsive to pathogens, the method comprising inserting at least one cis-acting element sufficient to direct pathogen elicitor-specific expression, pathogen-infection-specific expression, or both into the promoter of said gene, wherein the at least one cis-acting element comprises the nucleotide sequence of SEQ ID NO: 3 or 4 to produce the chimeric promoter.

30. A method for preparing a promoter capable of mediating local gene expression in plants upon pathogen infection, the method comprising operably linking a cis-acting element sufficient to direct elicitor-specific expression to a transcription initiation sequence of a promoter, wherein the cis-acting element comprises the nucleotide sequence of SEQ ID NO: 3 or 4.

31. The method of claim 29, further comprising inserting into the promoter at least one additional cis-acting element, wherein the at least one additional cis-acting element consists of an element with the nucleotide sequence of one of SEQ ID NO: 1-16, a homo-multimeric form of the elements with the nucleotide sequence selected from the group consisting of the nucleotide sequences of one of SEQ ID NO: 1-16 or a hetero-multimeric form of the elements with the nucleotide sequence selected from the group consisting of the nucleotide sequences of one of SEQ ID NO: 1-16.

Details for Patent 9,410,159

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2018-11-12
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2018-11-12
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2018-11-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.